3 GLP-1s are multi-system therapies
Aggressive hydration is also critical to manage renal load and prevent dehydration from suppressed thirst mechanisms
That said, clinical research gives us a fairly clear picture of how retatrutide dosing works
71.2 lbs on average) Retatrutide 9mg: 26.4% body weight reduction Tirzepatide/Zepbound (Phase 3 comparison, not head-to-head): ~20.9% Semaglutide/Wegovy (Phase 3 comparison, not head-to-head): ~14.9% Placebo: ~2.1% Note: These figures come from separate Phase 3 trials and are not direct head-to-head comparisons
Future Directions and Research Priorities Emerging Therapeutic Approaches Triple agonist retatrutide and combinations including cagrisema have progressed to phase 3 trials as obesity treatments with early data suggesting even greater weight loss than tirzepatide [83]
Side effects, particularly gastrointestinal symptoms, can be more disruptive in individuals who are not accustomed to chronic medication use
